Skip to main content
. Author manuscript; available in PMC: 2015 Apr 2.
Published in final edited form as: Support Care Cancer. 2014 Jun 26;23(1):55–59. doi: 10.1007/s00520-014-2326-9

Table 1. Baseline demographics.

Baseline demographics by type of chemotherapy or patients receiving fosaprepitant

AC (N=99) Platinum (N=81) Total (N= 180) p value
Age at time of chemo 0.0266a
 N 99 81 180
 Mean (SD) 53.3 (9.7) 56.4 (13.2) 54.7 (11.5)
 Median 55.0 57.0 56.0
 Range (31.0–74.0) (22.0–77.0) (22.0–77.0)
Gender <0.0001b
 Male 2 (2.0 %) 50 (61.7%) 52 (28.9 %)
 Female 97 (98.0 %) 31 (38.3 %) 128 (71.1 %)
Ethnicity 0.2069b
 White 91 (91.9%) 77 (95.1 %) 168 (93.3 %)
 Black 2 (2.0 %) 0 (0.0 %) 2 (1.1 %)
 Asian 0 (0.0 %) 1 (1.2 %) 1 (0.6 %)
 Hispanic 3 (3.0 %) 1 (1.2 %) 4 (2.2 %)
 Other 3 (3.0 %) 0 (0.0 %) 3 (1.7%)
 American Indian 0 (0.0 %) 1 (1.2 %) 1 (0.6 %)
 Middle Eastern 0 (0.0 %) 1 (1.2 %) 1 (0.6 %)
Primary cancer diagnosis <0.0001b
 Breast 98 (99.0 %) 4 (4.9 %) 102 (56.7 %)
 Lung 0 (0.0 %) 20 (24.7 %) 20 (11.1 %)
 GI 0 (0.0 %) 12 (14.8%) 12 (6.7%)
 Reproductive or genitourinary 1 (1.0 %) 15 (18.5 %) 16 (8.9%)
 Other 0 (0.0 %) 7 (8.6 %) 7 (3.9 %)
 Endo 0 (0.0 %) 6 (7.4 %) 6 (3.3 %)
 Head 0 (0.0 %) 17 (21.0%) 17 (9.4%)
Prior history of chemo <0.0001b
 No 84 (84.8 %) 40 (49.4 %) 124 (68.9 %)
 Yes 15 (15.2%) 41 (50.6 %) 56 (31.1 %)
Metastasis <0.0001b
 Yes 2 (2.0 %) 22 (27.2 %) 24 (13.3 %)
 No 97 (98.0 %) 59 (72.8 %) 156 (86.7%)
Corticosteroid use 0.3644b
 No 1 (1.0 %) 0 (0.0 %) 1 (0.6 %)
 Yes 98 (99.0 %) 81 (100.0 %) 179 (99.4 %)
Prior use of fosaprepitant b
No 99 (100.0 %) 81 (100.0 %) 180 (100.0%)
Prior use of aprepitant <0.0001b
 No 98 (99.0 %) 57 (70.4 %) 155 (86.1 %)
 Yes 1 (1.0 %) 24 (29.6 %) 25 (13.9 %)

AC anthracycline-cyclophosphamide

a

Kruskal Wallis

b

Chi-Square